Mavorixafor (AMD-070) is a potent and selective CXCR4 antagonist with an IC50 value of 13 nM for CXCR4 125I-SDF binding.

 

Brand: BCM

 

Target: CXCR

 

Signaling Pathways: Autophagy; GPCR/G Protein; Immunology/Inflammation

 

In Vitro: Mavorixafor (6.6 µM) significantly decreases the anchorage-dependent growth, migration, and matrigel invasion of the B88-SDF-1 cells. Mavorixafor shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2).

 

Melting Point: 108-110℃

 

Boiling Point: 597.0±50.0 °C(Predicted)

 

pKa: 11.65±0.10(Predicted)

 

Solubility: Soluble in DMSo; soluble in Ethanol. Insoluble in Water.

 

GHS: GHS07

 

Isomeric SMILES: C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3  

 

InChIKey: WVLHHLRVNDMIAR-IBGZPJMESA-N  

 

InChI: InChI=1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1

 

Attribute
[Chem Name]	N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine
[Synonym]	Mavorixafor; AMD-070
[CAS No.]	558447-26-0
[MDL No.]	MFCD11977316
[Formula]	C21H27N5
[Molecular]	349.47
[Form]	Brown Oil
[Storage]	Keep in dark place. Sealed in dry, 2-8°C

Goods Tag